CONTENTS VOL. 21, 2001

Volume 21, No 1

Preclinical studies

Different effects of vinblastine on the polymerization of isotypically purified tubulins from bovine brain – Israr A. Khan, Richard F. Ludueña 3–13

Effect of the antitumor drug vinblastine on nuclear β_{II}-tubulin in cultured rat kidney mesangial cells – Consuelo Walss-Bass, Jeffrey I. Kreisberg, Richard F. Ludueña 15–20

Reversal of tumor-induced immunosuppression by TGF-β inhibitors – Slawomir Wojtowicz-Praga 21–32

Discovery and preclinical antitumor efficacy evaluations of LY32262 and LY33169 – Thomas H. Corbett, Kathryn White, Lisa Polin, Juiwanna Kushner, Jennifer Paluch, Chuan Shih, Cora Sue Grossman 33–45

An overview on the antileukemic potential of D-homo-aza- and respective 17β-acetamido-steroidal alkylating esters – Charalambos Camoutsis, Dimitrios T.P. Trafalis 47–54

Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration – Moreno Cocchietto, Sonia Zorzet, Alenka Sorc, Gianni Sava 55–62

Phase I studies

A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design – S.M. Gadgeel, R.R. Boinpally, L.K. Heilbrun, A. Wozniak, V. Jain, B. Redman, M. Zalupski, R. Wiegand, R. Parchment, P.M. LoRusso 63–74

A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer – E. Claire Dees, Eric K. Rowinsky, Dennis A. Noe, Seamus O'Reilly, Alex A. Adjei, Kathy Elza-Brown, Ross C. Donehower 75–84

Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxy nucleotide MG98 given as a 21-day continuous infusion every 4 weeks – Alison J. Davis, Karen A. Gelmon, Lillian L. Siu, Malcolm J. Moore, Carolyn D. Britten, Nisha Mistry, Henry Klamut, Susan D'Aloisio, Martha MacLean, Nancy Wainman, Debbie Ayers, Patricia Firby, Jeffrey M. Besterman, Gregory K. Reid, Elizabeth A. Eisenhauer 85–97

Phase II studies

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma – Robert J. Motzer, Robert Amato, Mary Todd, Wen-J Poo Hwu, Roger Cohen, Jose Baselga, Hyman Muss, Michael Cooper, Richard Yu, Michelle S. Ginsberg, Michael Needle 99–101

A phase II study of rebeccamycin analog NSC 655649 in patients with metastic colorectal cancer – Sanjay Goel, Scott Wadler, Anthony Hoffman, Fabio Volterra, Cheryl Baker, Elliot Nazario, Percy Ivy, Alyson Silverman, Sridhar Mani 103–107

Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia – Dawn E. Colburn, Deborah A. Thomas, Francis J. Giles 109–111

Review

Current approaches to novel therapeutics in pancreatic cancer – Corina E. Akerele, Irina Rybalova, Howard L. Kaufman, Sridhar Mani 113–129

Instructions for authors 131–133

Volume 21, No 2

Special issue

Role of Modeling and Simulation in Clinical Development of Anticancer Agents

Alex Sparreboom and Mats O. Karlsson, guest editors

Introduction: Role of modeling and simulation in clinical development of anticancer agents – Alex Sparreboom, Mats O. Karlsson 139–140

Toxicity patterns of cytotoxic drugs – Etienne Chatelut, Jean-Pierre Delord, Pierre Canal 141–148

Chemotherapy individualization – Gareth J. Veal, Sally A. Coulthard, Alan V. Boddy 149–156

Noninvasive methods to study drug distribution – Ruediger E. Port, Walter Wolf 157–168

Use of positron emission tomography in anticancer drug development – Eric O. Aboagye, Patricia M. Price 169–181

Mechanistic models for myelosuppression – Lena E. Friberg, Mats O. Karlsson 183–194

Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: The capecitabine experience – Karen S. Blesch, Ronald Gieschke, Yuko Tsukamoto, Bruno G. Reigner, Hans U. Burger, Jean-Louis Steimer 195–223

Pharmacokinetic–pharmacodynamic guided trial design in oncology – Ch. van Kesteren, R.A.A. Mathôt, J.H. Beijnen, J.H.M. Schellens 225–241

Clinical trial design for target specific anticancer agents – Ronald Hoekstra, Jaap Verweij, Ferry A.L.M. Eskens 243–250

Instructions for authors 251–253

Volume 21, No 3

Preclinical studies

The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation – L. A. Kraus, S. K. Samuel, S. M. Schmid, D. J. Dykes, W. R. Waud, M. C. Bissery 259–268

The alkylating agent penclomedine induces degeneration of Purkinje cells in the rat cerebellum – S. O'Reilly, E. O'Hearn, R. F. Struck, E. K. Rowinsky, M. E. Molliver 269–279

Immunomodulatory effects of docetaxel on human lymphocytes – M.-S. Si, D. K. Imagawa, P. Ji, X. Wei, B. Holm, J. Kwok, M. Lee, B. A. Reitz, D. C. Borie 281–290

Phase I and pharmacokinetic studies

Effect of valspodar on the pharmacokinetics of unbound paclitaxel – A. J. ten Tije, T. W. Synold, D. Spicer, J. Verweij, J. H. Doroshow, A. Sparreboom 291–298

Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model – D. K. McClish, J. D. Roberts 299–308

Clinical review

Positron emission tomography (PET): Expanding the horizons of oncology drug development – L. A. Hammond, L. Denis, U. Salman, P. Jerabek, C. R. Thomas, Jr., J. G. Kuhn 309–340

Phase II studies

Phase II trial of ZD1839 (IRESSA™) in patients with advanced renal cell carcinoma – B. Drucker, J. Bacik, M. Ginsberg, S. Marion, P. Russo, M. Mazumdar, R. Motzer 341–345

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer – C. Dittrich, V. Dieras, P. Kerbrat, C. Punt, R. Sorio, F. Caponigro, X. Paoletti, C. de Balincourt, D. Lacombe, P. Fumoleau 347–352

A phase II trial of pemetrexed in patients with metastatic renal cancer – R. Thödtmann, T. Sauter, S. Weinknecht, L. Weissbach, J. Blatter, U. Ohnmacht, A.-R. Hanauske 353–358

Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer – L. D. Lago, M. F. Richter, A. I. Cancela, S. A. Fernandes, K. T. Jung, A. C. Rodrigues, T. D. Costa, L. P. Di Leone, G. Schwartsmann 359–366

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer – G. Liu, K. Oettel, H. Bailey, L. V. Ummersen, K. Tutsch, M. J. Staab, D. Horvath, D. Alberti, R. Arzoomanian, H. Rezazadeh, J. McGovern, E. Robinson, D. DeMets, G. Wilding 367–372

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a gynecologic oncology group study – D. K. Armstrong, J. A. Blessing, K. Y. Look, R. Schilder, E. R. Nunez 373–377

1st ISC International Conference on Cancer Therapeutics – Molecular Targets, Pharmacology and Clinical Applications 379

Instructions for authors 381–383

Volume 21, No 4

Preclinical studies

In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176 – M. Takagi, T. Honmura, S. Watanabe, R. Yamaguchi, M. Nogawa, I. Nishimura, F. Katoh, M. Matsuda, H. Hidaka 387–399

Biological role of adduct formation of the ruthenium (III) complex nami-A with serum albumin and serum transferrin – A. Bergamo, L. Messori, F. Piccioli, M. Cocchietto, G. Sava 401–411

Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells – F. Barbieri, A. Alama, B. Tasso, V. Boido, C. Bruzzo, F. Sparatore 413–420

Effect of novel benzoylphenylurea derivatives on DNA polymerase α activity using the synthesome-based *in vitro* model system – W. Abdel-Aziz, R. J. Hickey, M. J. Edelman, L. H. Malkas 421–428

Phase I and pharmacokinetic studies

A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors – S. M. Chang, J. G. Kuhn, H. I. Robins, S. C. Schold, A. M. Spence, M. S. Berger, M. P. Mehta, I. Pollack, M. Gilbert, M. Prados 429–433

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism – A. Font, J. M. Sánchez, M. Tarón, E. Martinez-Balibrea, J. J. Sánchez, J. L. Manzano, M. Margelí, M. Richardet, A. Barnadas, A. Aad, R. Rosell 435–443

Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D_3 analogue, in a phase I study of patients with advanced malignancies – R. Wieder, S. C. Novick, B. W. Hollis, M. Bryan, S. M. Chanel, K. Owusu, D. Camastra, T. Saunders, L. Pliner, J. Harrison, P. Bonate, T. Williams, S. Soignet 445–452

Phase II studies

A randomized phase II evaluation of bryostatin-1 (NSC#339555) in persistent or recurrent squamous cell carcinoma of the cervix: a Glynecologic Oncology Group Study – D. K. Armstrong, J. A. Blessing, J. Rader, J. I. Sorosky 453–457

Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes – R. Sánchez, E. E. Steban, I. Palacio, Y. Fernández, I. Muñiz, J. M. Vieitez, J. Fra, P. Blay, N. Villanue, E. Uña, B. Mareque, E. Estrada, J. M. Buesa, A. J. Lacave 459–463

A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer – M. Hussain, U. Vaishampayan, L. K. Heilbrun, V. Jain, P. M. LoRusso, P. Ivy, L. Flaherty 465–471

A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma – K. Bélanger, D. MacDonald, G. Cairncross, S. Gertler, P. Forsyth, S. Burdette-Radoux, J. Bergeron, D. Soulières, S. Ludwin, N. Wainman, E. Eisenhauer 473–480

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma – P. Reichardt, K. Oechsle, D. Pink, C. Bokemeyer, F. Schneller, R. Issels, L. Kanz, J. T. Hartmann 481–486

1st ISC International Conference on Cancer Therapeutics – Molecular Targets, Pharmacology and Clinical Applications 487

Volume Table of Contents for 2003 489–492

Instructions for authors 493–495